Genetic Profiling for Personalized Opioid Dosing and Adverse Effect Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for surgical pain management and anesthesia face challenges due to inter-individual variability in drug response, leading to inadequate pain relief and serious opioid-related adverse effects, which are not effectively addressed by existing technologies.
Innovation Solution
A method involving genetic profiling using nucleic acid samples to identify polymorphisms associated with pain perception and opioid-related adverse effects, combined with non-genetic risk factors, to determine a patient's susceptibility to adverse effects from anesthesia and opioids, allowing for personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anesthesia and opioid medications are administered to achieve adequate pain relief, then pain relief is improved, but serious adverse effects such as respiratory depression increase
Solution Approach 1:
The patent performs genetic profiling and risk assessment before administering anesthesia or opioids to identify patients at high risk for adverse effects. This preliminary action enables clinicians to select alternative medications or adjust dosages in advance, preventing respiratory depression and other serious side effects while still providing adequate pain relief.
Solution Approach 2:
The patent changes the parameter of medication selection and dosage based on genetic profile characteristics. By analyzing genetic variants associated with opioid metabolism and pain perception, the system tailors the type and amount of analgesics administered to each patient, optimizing pain relief while minimizing adverse effects such as respiratory depression.
2Reliability
If higher doses of opioids are administered to maximize pain relief, then pain relief is improved, but respiratory depression and other serious side effects increase
Solution Approach 1:
The patent adjusts the dosage parameter of opioids based on genetic profile analysis. Patients with genetic variants associated with reduced opioid metabolism or increased sensitivity receive lower doses, while those with faster metabolism or reduced sensitivity may receive higher doses. This personalized dosing maximizes pain relief while minimizing respiratory depression and other adverse effects.
3Object-affected harmful factors
If genetic profiling and personalized treatment approaches are implemented, then adverse effects are minimized, but device complexity and implementation requirements increase
Solution Approach 1:
The patent segments the complex genetic profiling process into distinct components: nucleic acid sample collection, DNA extraction, genotyping for specific polymorphisms, and risk assessment based on identified variants. This segmentation allows the system to focus on specific genetic markers associated with opioid response and pain perception, simplifying the overall process while maintaining accuracy in predicting adverse effects.
Data Source
AI summary
Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and/or serious side effects from anesthesia, analgesics, and/or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.